Cargando…
A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model....
Autores principales: | Sadiq, Muhammad W., Nielsen, Elisabet I., Khachman, Dalia, Conil, Jean-Marie, Georges, Bernard, Houin, Georges, Laffont, Celine M., Karlsson, Mats O., Friberg, Lena E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376394/ https://www.ncbi.nlm.nih.gov/pubmed/27578330 http://dx.doi.org/10.1007/s10928-016-9486-9 |
Ejemplares similares
-
Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime
por: Thorsted, Anders, et al.
Publicado: (2020) -
Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin
por: Park, Min-Ho, et al.
Publicado: (2017) -
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007) -
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
por: Netterberg, Ida, et al.
Publicado: (2017) -
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)